A recent retrospective analysis demonstrated that positive clinical outcome of leiomyosarcoma (PFS: 6.8 vs. 3.2 months; OS: 14.9 vs. 8.5 months) and angiosarcoma (PFS was 9.3 vs. 4.5 months; OS 20.6 vs. 10.8 months) patients treated with gemcitabine was linked to high hENT1 tumor expression levels (38). The gene discussed is SLC29A1; the disease is leiomyosarcoma.